AR and neoplasm: It is due to good drug loading ability, high stability, and triggered release that the as-designed Di-PP/AR-siRNA/DTX nanosystem obtained higher cytotoxicity against LNCaP cells in vitro (Figure 7B(II),C,D), significantly decreased AR protein expression (Figure 7A), and obvious tumor inhibition in vivo (Figure 8B–D).